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Cutaneous squamous cell carcinoma (cSCC) is a keratinocyte-derived skin tumor. It is the second-most-
common cancer affecting the Caucasian population and is responsible for >20% of all skin-cancer-
related deaths. The estimated incidence of non-melanoma skin cancer in the USA is >1 000 000 cases per
year, of which roughly 20–30% are squamous cell carcinoma. To better understand and treat this
challenging cancer, current research focuses on development of novel strategies to improve the
understanding of tumor biogenesis on an individual basis. microRNAs are becoming important
biomarkers in the diagnosis, prognosis and treatment of cSCC. This review describes the current
knowledge on miRNA expression in cSCC and its role as a biomarker for personalized medicine.
Introduction
More than 3.5 million cases of non-melanoma skin cancer are
diagnosed each year in the USA, with treatment costs reaching US
$1.4 billion, making it the fifth-most-costly cancer for the Medi-
care population [1,2]. It has been estimated that solar ultraviolet
(UV) radiation accounts for 93% of skin cancers [3]. Whereas
cutaneous squamous cell carcinoma (cSCC) is strongly related to
constant or cumulative sun exposure, malignant melanoma and
basal cell carcinoma have been linked to intermittent UV exposure
especially at a younger age [1]. cSCC is an epidermal keratinocyte-
derived skin tumor that is the second-most-common cancer af-
fecting the Caucasian population [4], it displays a constantly
increasing incidence estimated at 200 000 new cases each year
in the USA [5,6] and accounts for 20% of all skin-cancer-related
deaths [7]. A recently published systematic review of worldwide
non-melanoma skin cancer reports that Australia appears to have
the highest incidence rates for cSCC at >1000/100 000 population
per year [8].
The past few years have been characterized by significant
progress in the development of biomarkers in all fields of medi-
cine, including oncology. These specific biomarkers play a crucial
part in the understanding of pathomechanisms that drive tumor
initiation, progression and metastasis. According to Nalejska et al.
[9], biomarkers in oncology provide tools to characterize cancer
signatures and can be divided into four groups: diagnostic, prog-
nostic, treatment and prevention groups. Diagnostic biomarkers
are identified by key mutation and molecular pathways involved
in tumor development. Prognostic biomarkers identify somatic
germline mutations, dysregulation of microRNA (miRNA) expres-
sion, DNA methylation and circulating tumor cells. Treatment
and prevention biomarkers guide the individual therapy by esti-
mating different outcome risks. The National Cancer Institute
defines biomarkers as a biological molecule found in the blood,
other fluids or tissues that is a sign of a normal or abnormal
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